VIDEO: Examining adjuvant chemotherapy in locally advanced cervical cancer
Click Here to Manage Email Alerts
In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed the “practice-changing” results from the OUTBACK trial.
Researchers designed the international, randomized, phase 3 trial, which was presented during a plenary session at the ASCO Annual Meeting, to evaluate the potential survival benefit of adjuvant chemotherapy given after standard chemoradiation compared with chemoradiation alone in patients with locally advanced cervical cancer.
After 5 years, the data showed no difference in progression-free survival between the two treatment arms.
“This is really important because it basically determines the adjuvant therapy regimen that will be given to patients with locally advanced cervical cancer,” Annunziata said.
Collapse
Mileshkin LR, et al. Late-Breaking Abstract 3. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts